Market closed
Avita Therapeutics/$RCEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Avita Therapeutics
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Ticker
$RCEL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
260
Website
RCEL Metrics
BasicAdvanced
$198M
-
-$2.39
1.55
-
Price and volume
Market cap
$198M
Beta
1.55
52-week high
$15.66
52-week low
$7.44
Average daily volume
205K
Financial strength
Current ratio
2.828
Quick ratio
2.374
Long term debt to equity
1,002.112
Total debt to equity
1,022.116
Interest coverage (TTM)
-0.27%
Management effectiveness
Return on assets (TTM)
-36.97%
Return on equity (TTM)
-230.96%
Valuation
Price to revenue (TTM)
3.025
Price to book
43.99
Price to tangible book (TTM)
-184.8
Price to free cash flow (TTM)
-3.336
Growth
Revenue change (TTM)
28.14%
Earnings per share change (TTM)
71.07%
3-year revenue growth (CAGR)
24.84%
3-year earnings per share growth (CAGR)
32.28%
What the Analysts think about RCEL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Avita Therapeutics stock.
RCEL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RCEL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RCEL News
AllArticlesVideos
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity
GlobeNewsWire·2 days ago
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
GlobeNewsWire·3 weeks ago
AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Avita Therapeutics stock?
Avita Therapeutics (RCEL) has a market cap of $198M as of April 05, 2025.
What is the P/E ratio for Avita Therapeutics stock?
The price to earnings (P/E) ratio for Avita Therapeutics (RCEL) stock is 0 as of April 05, 2025.
Does Avita Therapeutics stock pay dividends?
No, Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Avita Therapeutics dividend payment date?
Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Avita Therapeutics?
Avita Therapeutics (RCEL) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.